Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal)

  • Technology appraisal
  • TA564
  • Published: 

This guidance has been updated and replaced by NICE technology appraisal guidance 898.